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Appropriate control of ex vivo gene therapy
delivering basic fibroblast growth factor promotes
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vessels in rabbit model of hind limb ischemia
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Purpose: In our previous study, adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promoted
significant collateral vessel development in a rabbit model of hind limb ischemia. The present study examined how to
control the efficacy and safety of this gene therapy, and also evaluated the feasibility of repeat application of this
procedure.
Methods: Modified hFGF gene with the secretory signal sequence was adenovirally transferred to cultured autologous
fibroblasts, and various numbers of the cells (2  105, 1  106, 5  106, or 2.5  107) or vehicle was injected through
the left internal iliac artery in rabbits in whom the left femoral artery had been excised 21 days previously. Twenty-eight
days after cell administration, calf blood pressure ratio, angiographic score, blood flow in the internal iliac artery, and
capillary density of muscle tissue were measured to analyze collateral vessel development and tissue perfusion in the
ischemic limb. To assess delivery efficiency and viral contamination, the distribution of injected cells and the time course
of blood anti-adenovirus antibody titer were examined in rabbits treated with various numbers of gene-transduced cells.
In addition, animals received two injections, 21 days apart, of fibroblasts infected with adenovirus vector containing the
luciferase gene, and luciferase expression was measured to evaluate whether the present therapy is repeatable.
Results: At 28 days after cell administration, significant collateral vessel development without detectable side effects was
observed in rabbits who received 5 106 or 2.5 107 cells, compared with those who received vehicle, and no significant
development was detected in animals with fewer than 5  106 cells (P < .01 for calf blood pressure ratio and capillary
density, P < .05 for angiographic score and maximum blood flow). There was no difference in collateral augmentation
between rabbits with 5  106 and 2.5  107 cells. However, in animals with 2.5  107 cells a large number of injected
cells accumulated in the lungs, anti-adenovirus antibody titer increased significantly, and calf blood pressure in the left
hind limb of two rabbits decreased immediately after injection. Luciferase analysis showed very low gene expression after
repeated administration.
Conclusion: These findings suggest that 5  106 is a suitable number of cells to induce appropriate collateral vessel
development and minimize potential side effects of this procedure. Despite use of ex vivo gene transfer, repeat
administration of the cells was not feasible. (J Vasc Surg 2004;39:629-38.)
Clinical Relevance: Since the present study determined the appropriate conditions for effective and safe stimulation of
collateral vessels, the clinical relevance of the ex vivo therapy might be carried forward. However, the findings raised
another issue that should be resolved before clinical application; that is, the number of gene-transduced cells able to be
injected was strictly limited. To estimate the therapeutic range of cell number in humans, additional experiments using
large animals are desirable.
To enhance collateral vessel development for treatment
of vascular occlusive disease, a variety of techniques have
been presented for local delivery of angiogenic growth
factor, such as basic fibroblast growth factor (bFGF) or
vascular endothelial growth factor, among others. Direct
administration of recombinant protein to deliver these
growth factors was initially investigated,1,2 and subse-
quently several protocols for gene transfer were established
to realize more efficient and sophisticated delivery.3-5 In
previous studies we presented an alternative strategy using
ex vivo gene transfer of bFGF, and demonstrated signifi-
cant augmentation of collateral vessel development and
tissue perfusion in a rabbit model of hind limb ischemia.6
The concept of this strategy was that autologous fibro-
blasts, transduced with modified bFGF gene, were selec-
tively injected into the donor artery. The donor artery
indicates a potential origin of a collateral vessel network
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toward the ischemic lesion, and requires adequate blood
inflow for blood supply. The reason for using fibroblasts as
the delivery carrier was that the fibroblast is a non–blood
cell that is readily feasible for primary culture. On this
account, the gene-transduced fibroblasts were physically
trapped in peripheral small vessels of the donor artery, and
secreted bFGF for a certain period, because the modified
bFGF gene was fused with the secretory signal sequence of
interleukin-2.7,8 Angiogenesis and arteriogenesis com-
monly occur in small arteries and capillaries. This strategy
therefore achieves specific delivery of bFGF to the ideal
target to promote favorable collateral vessel development
with sufficient blood inflow. Further, with this strategy the
bFGF gene was transferred into fibroblasts with an adeno-
virus vector, because of its high efficiency of gene transfer9
and transient expression of the transduced gene.10,11 Tran-
sient gene expression would be a favorable feature for
safety, because long-term expression of growth factor gene
would increase the possibility of unexpected side effects.
Our therapeutic strategy has some unique features in
inducing effective development of collateral vessels. How-
ever, some issues must be resolved before clinical applica-
tion. Most important is how to control the effect and safety
of this therapy. Inasmuch as the bFGF gene was transferred
to all fibroblasts before administration, a variable factor that
influences performance of this therapy is the number of
administered fibroblasts. Our previous study only showed
data after administration of 5 106 gene-transduced fibro-
blasts. Further, there is little evidence of how non–blood
cells, in which an exogenous gene is transduced, function
and behave after administration into a peripheral artery. In
the present study we therefore determined a suitable cell
number to promote appropriate collateral vessel develop-
ment and minimize the possibility of side effects. In addi-
tion, we focused on repeat application of the ex vivo pro-
cedure. Because our previous study reported no significant
induction of humoral immune response against adenovirus
after injection of gene-transduced cells,6 we considered the
possibility that ex vivo therapy with an adenovirus vector
could be repeated without early elimination of the admin-
istered cells.
METHODS
Adenovirus. Replication-deficient recombinant ade-
novirus vector containing modified human bFGF gene
with the secretory signal sequence of interleukin-2 (AxCA-
MAssbFGF) was constructed with a method utilizing cos-
mid cassettes and adenovirus DNA-terminal protein com-
plex (the COS-TPC method).12,13 Modified human bFGF
is more stable than the original human bFGF,8 and synthe-
sized bFGF can be secreted to the outside of cells, because
of the added secretory signal sequence. Our previous study
showed that rabbit fibroblasts infected with AxCAMAss-
bFGF significantly secreted bFGF into the culture medi-
um.6 AxCALacZ containing the Escherichia coli LacZ gene
in the same expression unit was used as a control vector for
evaluation of side effects, and AxCAluc containing re-
combinant luciferase gene (luc) was used to evaluate in
vivo expression of the transduced gene.
Animal model of chronic hind limb ischemia. For
evaluation of angiogenic responses in vivo, we used a rabbit
model of hind limb ischemia.6,14 Male Japanese White
rabbits weighing 3.0 to 3.5 kg (Saitama Rabbitry, Saitama,
Japan) were anesthetized, and the left femoral artery was
completely excised, from its proximal origin to the bifurca-
tion formed by the saphenous and popliteal arteries.14
Before closure of the wound, a 10 20 mm section of skin
was obtained for primary culture of fibroblasts (Fig 1). All
protocols were in accordance with the Guide for Animal
Experimentation of The University of Tokyo.
Ex vivo gene transfer. Fibroblasts were cultured from
the resected skin tissue and grown to confluence in
100-mm dishes, as described.6 At 20 days after femoral
artery excision the fibroblasts (passage 3) were infected in
vitro with AxCAMAssbFGF at 20 plaque-forming units
(pfu) per cell and incubated for 24 hours.15 At 21 days after
removal of the femoral artery, a 3F end-hole infusion
catheter (Rapid Transit; Cordis, Miami, Fla) was intro-
duced into the carotid artery and positioned in the left
internal iliac artery. After washing three times with phos-
phate-buffered saline solution, the infected fibroblasts were
suspended in 4.5 mL of Dulbecco modified Eagle mini-
mum essential medium (DMEM; Gibco BRL, Grand Is-
land, NY) with 2% fetal bovine serum (DMEM 2%), then
injected through the infusion catheter (Fig 1). In this study
various numbers of gene-transduced fibroblasts were ad-
ministered in four groups of six rabbits each, as follows: 2
105, 1  106, 5  106, and 2.5  107. Another group of
seven rabbits was injected with 4.5 mL of DMEM 2%
(vehicle) as control.
Assessment of collateral vessel development and
tissue perfusion. Calf blood pressure (BP) in both hind
limbs was measured with a 2.5-cm wide cuff and Doppler
scanning probe, and the calf BP ratio was calculated as the
ratio of left systolic pressure to right systolic pressure.2 Calf
BP ratio was assessed four times: immediately after femoral
artery excision, and immediately before, immediately after,
and 28 days after administration of infected cells or vehicle.
At 28 days after injection of gene-transduced fibroblasts or
vehicle, selective internal iliac arteriography was performed,
and angiographic score was calculated, as described.5 Be-
fore angiography, resting blood flow in the left internal iliac
artery and maximum blood flow after papaverine injection
were measured with a Doppler guide wire, as described.16
After the animals were killed, tissue specimens were ob-
tained as transverse sections from the left semimembranous
muscle. Frozen sections were cut (two sections per animal),
capillary endothelial cells were stained with the indolyl-
tetrazolium method,17 and capillaries were counted in 20
different fields from the two sections to determine capillary
density.2
Distribution of administered cells. To evaluate the
distribution of injected cells, cultured fibroblasts were ra-
diolabeled with indium 111–oxine solution (Amersham
Pharmacia Biotech, Little Chalfont, England) according to
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the protocol described.6 At 21 days after removal of the left
femoral artery the labeled fibroblasts suspended in 4.5 mL
of DMEM 2% were injected through the left internal iliac
artery. We tested three cell numbers in this study: 1  106
(n  5), 5  106 (n  7), and 2.5  107 (n  5). Treated
animals were killed 5 hours after cell administration, and
above-knee muscles, below-knee muscles, and skin were
taken from the bilateral hind limbs, and internal organs
were collected. The distribution (percentage) of cells in
each muscle or organ was determined as described.6 In
addition, the cell number distributed to each muscle or
organ was calculated as (Distribution %)(Administered
cell number)/100.
In vivo expression of bFGF and side effects. At 21
days after removal of the left femoral artery, 5 106 or 2.5
 107 fibroblasts treated with AxCAMAssbFGF were in-
jected through the left internal iliac artery. For time course
study the rabbits were killed, at 7, 14, 21, and 28 days after
injection (n  5 at each time point), and various samples
were taken from the bilateral adductor muscles, lung, heart,
liver, kidney, spleen, testis, serum, and total blood. Some
rabbits (n  5 at each time point) were injected with 4.5
mL of DMEM 2% (vehicle), and another group of animals
(n 5) was killed at 21 days after femoral artery excision as
control (control). To determine in vivo bFGF expression,
the left adductor muscle (1 g), lung (0.5 g), and liver (0.25
g) were analyzed with the Western blot technique, after
concentration with heparin-sepharose CL-6B (Amersham
Pharmacia Biotech), as described.18 The primary antibody
used in the Western blot technique recognizes endogenous
rabbit bFGF and also the bFGF synthesized by AxCA-
MAssbFGF infection. Serum bFGF concentration was
quantified with an enzyme-linked immunosorbent assay (R
& D Systems, Minneapolis, Minn), and anti-adenovirus
antibody titer with a neutralization test (SRL, Tokyo, Ja-
pan).6 Side effects were assessed with blood examination
and histologic evaluation. On the time course blood sam-
ples we performed a complete blood cell count and blood
chemical tests (SRL), including aspartate aminotransferase,
alanine aminotransferase, lactate dehydrogenase, total bili-
rubin, alkaline phosphatase, urea nitrogen, and creatinine
concentration. Further, each tissue sample was embedded
in paraffin, and sections were stained with hematoxylin-
eosin (HE) or elastica–van Gieson (EVG) and analyzed.
Fig 1. Experimental protocol for intra-arterial injection of various numbers of gene-transduced fibroblasts.
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For evaluation of the inflammatory reaction in host tissue,
frozen sections of the left adductor muscle were immuno-
stained with monoclonal antibody against rabbit macro-
phage (RAM-11, 1:50; DAKO, Copenhagen, Denmark),
CD18 leukocyte (L13/64, 1:100; Serotec, Oxford, En-
gland), or T lymphocyte (L11/135, 1:100; Serotec), as
described.19,20
Administration of gene-transduced cells to venous
system. To assess the side effects of gene-transduced cells
that entered the venous system, AxCAMAssbFGF-treated
fibroblasts (1 107) were injected through the iliac vein of
normal rabbits, and the influence on the lung was analyzed.
Blood gas analysis was carried out at 1, 4, 7, 14, 21, and 28
days after intravenous injection of infected cells. Lung
samples were obtained at days 7 and 28, and were examined
histologically (HE, EVG). Control animals were treated
with AxCALacZ.
Repeated administration of gene-transduced fibro-
blasts. To evaluate whether the present ex vivo therapy is
repeatable, AxCAluc-treated fibroblasts were adminis-
tered twice, at an interval of 21 days. First, 5  106
fibroblasts, infected with AxCAluc, were injected
through the left internal iliac artery 21 days after removal of
the left femoral artery (first challenge). Twenty-one days
later AxCAluc-treated fibroblasts (5 106) were admin-
istered to the same rabbits in the same manner (second
challenge), and the animals were killed on day 7, 14, 21, or
28 after the second challenge (n 5 at each time point) for
sampling the left above-knee muscles (repeat group). An-
other group of rabbits (n  5 at each time point) was
injected with AxCAluc-treated fibroblasts (5  106) 21
days after administration of noninfected fibroblasts as con-
trol (control group). Each sample was weighed (WWhole),
minced, and homogenized. A certain volume of the ho-
mogenized sample (approximately 0.5 g, WSample) was
lysed in 1 mL of luciferase cell culture lysis buffer (Promega,
Madison, Wis), and the volume of the lysate was measured
(VLysate). After 100 L of luciferase substrate (Promega)
was added to 20 L of each lysate, luciferase activity was
measured with a luminometer (Lumat LB9507; Berthold
Technologies, Bad Wildbad, Germany), and luciferase con-
centration (CSample) was calculated from the luciferase ac-
tivity with a standard curve made by purified firefly lucif-
erase (Promega).21 Luciferase content of above-knee
muscles was calculated as: CSample  (WWhole/WSample)
 (VLysate/20L).
Statistical analysis. Counting for determination of
angiographic score and capillary density was performed by a
single student helper in a blind fashion. Results are ex-
pressed as mean  SD. The Tukey-Kramer method was
used for analysis of collateral vessel development and tissue
perfusion. Student’s t test was used for analysis of the
distribution of administered cells. Repeated-measures anal-
ysis of variance was used for analysis of systemic bFGF
concentration, after subtracting preinjection data from the
data at each time point. Repeated-measures analysis of
variance, after logarithmic transformation followed by a
simple main effects test, was used for analysis of anti-
adenovirus titer. All data were considered significant at P
.05. All statistical analyses were performed with SAS version
8.2 (SAS Institute, Cary, NC).
RESULTS
Assessment of collateral vessel development and
tissue perfusion. Calf BP ratio showed no significant dif-
ference between all groups before administration of cells or
vehicle. At 28 days after injection calf BP ratio in the 5 
106 and 2.5  107 groups was significantly higher than in
the other three groups, whereas no significant difference
was detected between the 5 106 and 2.5 107 groups or
between the other three groups. Meanwhile, calf BP de-
creased to zero only in two rabbits in the 2.5  107 group
when measured immediately after injection to evaluate the
influence of intra-arterial injection of fibroblasts (Fig 2).
Angiograms obtained 28 days after injection showed well-
developed collateral vessels in the 5  106 and 2.5  107
groups compared with the 2  105, 1  106, and vehicle
groups (Fig 3, a-e), which coincided with the angiographic
score (Fig 3, f). Capillary density in the 5 106 and 2.5
107 groups was significantly higher than in the other three
groups at 28 days after injection (Fig 4, a). Furthermore, in
the 5  106 and 2.5  107 groups, blood flow in the left
internal iliac artery at rest was significantly higher than in
the vehicle group (Fig 4, b), and maximum blood flow was
significantly greater than in the other three groups (Fig 4,
c).
Distribution of administered cells. Distribution
data (%) showed that about 45% of labeled cells accumu-
lated in the above-knee and below-knee muscles of the left
hind limb in animals treated with 1  106 or 5  106 cells
(Fig 5, a and b). Only in rabbits treated with 2.5  107
cells, great accumulation was observed in the lungs, but
only 10% of labeled cells accumulated in the above-knee
and below-knee muscles (Fig 5, c). Although the distribu-
tion (%) in the above-knee and below-knee muscles of the
left hind limbs differed according to the number of injected
cells, there was no significant difference in accumulated cell
number between animals treated with 5  106 and 2.5 
107 cells (Fig 5, d).
In vivo expression of bFGF protein. The Western
blot technique showed local accumulation of expressed
bFGF. In rabbits treated with 5  106 or 2.5  107 cells,
bFGF accumulation in the adductor muscle was increased 7
and 14 days after cell administration, compared with that in
control and vehicle-treated animals (Fig 6, a and b). bFGF
accumulation decreased thereafter, although the amount of
bFGF on days 21 and 28 was slightly higher than that in
vehicle-treated rabbits. At 7 days after cell injection bFGF
accumulation in the adductor muscle was increased in
rabbits treated with 2.5  107 cells, compared with those
treated with 5  106 cells, but no distinct difference was
detected between the two groups on days 14, 21, and 28.
In the lung and liver the time course of bFGF level revealed
no remarkable difference from that in control animals (Fig
6, c and d).
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Systemic bFGF level and anti-adenovirus antibody
titer. Time course analysis of systemic bFGF level showed
no significant increase in bFGF in rabbits administered 5
106 or 2.5  107 cells or vehicle, and there was no signifi-
cant difference between the three groups (Fig 7, a). Anti-
adenovirus titer in animals injected with 2.5 107 cells was
significantly higher than that in animals with 5  106 cells
on days 14, 21, and 28 (Fig 7, b).
Side effects and inflammatory reactions. Neither
complete blood cell count nor blood chemical tests showed
any abnormal data in animals treated with 5 106 or 2.5
107 cells at any time point after cell injection (data not
shown), and histologic studies with HE and EVG staining
revealed no fibrosis, infarction, degeneration, or other ab-
normal changes in any tissues up to day 28 (data not
shown). Inflammatory reaction in the left adductor muscle
was evaluated with immunostaining for macrophages,
CD18 leukocytes, or T lymphocytes, and no remarkable
infiltration of these cells was observed at 7 days after injec-
tion, as compared with vehicle-treated samples (Fig 8,
online only).
Intravenous injection of gene-transduced fibro-
blasts. Blood gas analysis showed no significant changes in
PaO2, PaCO2, or other parameters throughout the time
course after injection of AxCAMAssbFGF-treated cells,
and no difference compared with AxCALacZ-treated con-
trol (Fig 9, a and b, online only). In addition, histologic
studies showed no abnormal findings, such as fibrosis,
compared with control at 7 and 28 days after injection (Fig
9, c and d, online only).
Repeated administration of gene-transduced fibro-
blasts. In the control group, marked increase of luciferase
expression was observed in the left above-knee muscles,
which was maximal 7 days after the second challenge and
decreased thereafter (Fig 10). In contrast, in the repeat
group, which received injection of AxCAluc-treated cells
twice, very low level expression of luciferase was detected
throughout the time course (Fig 10).
DISCUSSION
We administered various numbers of AxCAMAss-
bFGF-treated fibroblasts into the rabbit ischemic hind limb
through an intra-arterial catheter, and several findings sug-
gest that injection of 5  106 fibroblasts is a suitable
amount to induce appropriate development of collateral
vessels and possibly prevent side effects in a rabbit model of
chronic hind limb ischemia.
First, a certain cell number was required for significant
induction of collateral vessels (minimum requirement).
Despite no significant increase of collateral vessel develop-
ment in the 2  105 and 1  106 groups, well-developed
collateral vessels were quickly detected in the animal groups
treated with more than 5 106 cells. That is, if the number
of injected fibroblasts was less than the minimum require-
ment, which was between 1  106 and 5  106, adminis-
tration of gene-transduced cells promoted no meaningful
effect. The volume of ischemic tissue must be one critical
factor that determines minimum requirement. In addition,
the cells’ ability to release bFGF might also be important.
The conditions of adenovirus infection, such as virus con-
centration, possibly influence the ability of bFGF release.
We further speculate that the level of ischemia of the tissue
is another important factor that determines minimum re-
quirement, because our previous study showed that collat-
eral vessel development in cell-administered tissues de-
pended on the level of ischemia in the tissues.6 Of interest,
Fig 2. Calf blood pressure ratio immediately after femoral artery excision, and immediately before, immediately after,
and 28 days after cell administration. At 28 days there were significant differences between each group in line * and each
group in line † (P  .01). There were no significant differences among the groups within each line.
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two study groups1,22 reported a similar dose-response pat-
tern in their studies with naked DNA of acidic FGF gene or
bFGF protein.
Second, in considering the suitable cell number, ad-
ministration of larger numbers of cells did not induce
further development of collateral vessels above a certain
level. Indeed, all parameters of collateral vessel augmenta-
tion in the present study revealed no significant difference
between the 5  106 and 2.5  107 groups. One possible
explanation is the capacity of the limb muscles to retain the
cells in their capillaries and small arteries. At 5 hours after
injection of labeled fibroblasts, the number of accumulated
cells in the left hind limb muscles showed no significant
difference between animals treated with 5 106 and 2.5
107 cells, whereas the cell distribution (%) revealed greater
cell accumulation in the lungs of rabbits treated with 2.5
Fig 3. Selective internal iliac angiograms of rabbits at 28 days after injection of vehicle (a) and 2  105 (b), 1  106
(c), 5 106 (e), and 2.5 107 (e) AxCAMAssbFGF-tranduced fibroblasts. Arrow, internal iliac artery. f, Development
of collateral vessels was quantified by angiographic score. There were significant differences between each group in line
* and each group in line † (P  .05). There were no significant differences among groups within each line.
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107 cells. These findings suggest that surplus cells exceed-
ing the capacity of the tissue overflowed into the venous
system and were trapped in the lungs, increasing the possi-
bility of unexpected pulmonary side effects. Results of the
Western blot technique on the left adductor muscle sam-
ples showed no notable difference in bFGF expression
between rabbits treated with 5  106 and 2.5  107 cells,
supporting the above concept.
Another important finding was that calf BP ratio de-
creased to zero immediately after injection in two rabbits in
the group treated with 2.5  107 cells, which indicated
worsening of ischemia. However, no significant decrease in
calf BP ratio was detected after injection of 5 106 or fewer
cells. These findings indicate that the excessive fibroblasts
behaved like emboli in the capillaries and small arteries, and
reduced peripheral blood flow immediately after injection,
Fig 4. a, Capillary density of left semimembranous muscle. b, In
vivo blood flow of left internal iliac artery at rest. c, Maximum in
vivo blood flow of left internal iliac artery. There were significant
differences between each group in line * and each group in line † (P
 .01 for capillary density; P  .05 for maximum blood flow).
There were no significant differences between groups within each
line. For blood flow at rest (b) there were significant differences
between each group in line ‡ and the vehicle group (P .05), but
no significant differences among the groups within this line.
Fig 5. Distribution of indium 111–labeled fibroblasts in organs
and tissues at 5 hours after injection of 1  106 cells (a), 5  106
cells (b), and 2.5  107 cells (c) into the left internal iliac artery.
Data are presented as percentage of radioactivity distributed in
each tissue relative to total radioactivity of administered cells. d,
Cell number of 111In-labeled fibroblasts in above-knee and below-
knee muscles of left hind limb, lung, and liver at 5 hours after
injection of 1  106, 5  106, and 2.5  107 cells into the left
internal iliac artery. *P  .001. AK, Above-knee muscles; BK,
below-knee muscles; Lt, left; Rt, right; Kd,; kidney; Ht, heart; Spl,
spleen; Test, testis; NS, no significant difference.
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which is possibly critical in ischemic tissue. Serum anti-
adenovirus antibody level in rabbits treated with 2.5 107
cells was significantly higher than that in animals treated
with 5  106 cells, indicating that the host was contami-
nated with viral particles. This might be because three
washes after viral infection was insufficient to remove viral
particles from 2.5  107 cells. Because the adenovirus
vector used in this procedure is replication-deficient, con-
tamination with viral vector may not induce severe side
effects; however, attention should be paid to the appear-
ance of replication-competent viruses.
To apply the study protocol to the clinical setting, it is
necessary to assess safety in other nonischemic tissues and
organs. Although the maximum number of injected cells
was five times that in our previous study, no detectable
change was observed in the evaluations performed. One
possible reason is that there was no significant increase in
systemic bFGF level over the course of the study. If secreted
bFGF completely entered the bloodstream, 5  106 cells
would be enough to significantly elevate the systemic bFGF
level, because in vitro analysis in the previous study showed
that rabbit fibroblasts treated in the same manner secreted
25 pg of bFGF per 1000 cells per 24 hours into the culture
medium.6 The binding ability between bFGF and proteo-
glycans of the extracellular matrix23 might function to
maintain bFGF in the targeted tissues and contribute to
continuing the effects of bFGF. In our previous study a
slightly increased amount of bFGF was detected in the left
adductor muscle until 28 days after cell injection, although
Fig 6. bFGF accumulation in left adductor muscle (a, b), lung
(c), and liver (d) with Western blot technique. b, bFGF accumu-
lation of control animals (21 days after femoral artery excision) was
similar to that in vehicle-treated animals. PC, Positive control;
vehicle, vehicle-treated sample; CM, left adductor muscle sample
from control animal; CLU, lung sample from control animal; CLI,
liver sample from control animal; d, days after infection.
Fig 7. a, Time course of systemic bFGF level measured with
ELISA. b, Time course of anti-adenovirus antibody titer quantified
with neutralizing test. Titers are shown as dilution ratio, and titers
less than 1:4 were assigned a value of 1. * P .0001 (5 106 cells
vs 2.5  107 cells). pre, Preinjection; d, days after injection.
Fig 10. Expression of luciferase in left above-knee (AK) muscles
of rabbits. d, Days after second challenge.
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immunohistologic analysis revealed that the number of
bFGF-positive cells in the sample muscle sample returned
to the control level by day 14.6 Another possible explana-
tion for the negative findings in the safety assessment is that
the number of gene-transduced cells was too low to induce
any detectable abnormality in the evaluations in the present
study. Especially in the lungs of the animals treated with 2.5
 107 cells, the Western blot technique revealed no detect-
able increase in bFGF, although approximately 1  107
cells were distributed to the lungs in these animals. We
speculate that even the amount of bFGF secreted by 1 
107 cells might be minimal, compared with that of bFGF
that the entire bilateral lung tissue contained. Indeed, in
our previous study immunohistologic analysis showed that
no significant change in the number of bFGF-positive cells
was detected in the lungs.6 Intravenous injection of 1 
107 AxCAMAssbFGF-treated fibroblasts also produced no
detectable changes in blood gas analysis or histologic find-
ings, which supports these results. Thus the number of cells
used in this protocol might be within safety limits.
A disappointing result of the present study is that
repeated application of this ex vivo gene therapy did not
appear to provide additional efficacy. In several experiments
with animal models administration of adenovirus vector
induced humoral and cellular immune responses against
adenovirus, which possibly limited expression of the trans-
duced gene. Contrarily in the present study, few particles of
the adenovirus vector were directly administered into the
host artery, as a result of ex vivo gene transfer. Indeed, in
both of our studies titers of serum anti-adenovirus antibody
remained at less than 1:100 up to 28 days after administra-
tion of 5  106 cells,6 and immunohistologic analysis
revealed no notable inflammatory infiltration in the left
thigh muscles. Further, a recent study reported that re-
peated treatment with adenovirus vector was feasible in
mice with anti-adenovirus antibody titer of 1:600.24 We
therefore hypothesize that the gene-transduced cells of the
second challenge could escape early elimination through
humoral immune responses, then function for a certain
period. However, luciferase analysis in the present study
showed very low gene expression even at 7 days after
repeated administration of AxCAluc-treated cells, which
contradicts this hypothesis. There is a possibility that neu-
tralizing antibody at a titer of less than 1:100 eliminates the
gene-transduced fibroblasts, although a more probable
mechanism for the early decrease in gene expression might
be cytotoxic immune reaction of T cells. Yang et al25 found
that in a mouse lung model cellular immune responses after
the second adenovirus challenge occurred earlier than those
after the first challenge. To prolong the life of repeatedly
administered cells, it might therefore be necessary to sup-
press host immune responses with an immunosuppressive
drug, but immunosuppression possibly would inhibit de-
velopment of collateral vessels, because the inflammatory
reaction around small arteries induces arteriogenesis.26
Thus we consider that application of a newer generation of
adenovirus vector is more practical than repeated treatment
to prolong the duration of gene expression with the present
strategy. However, if a newer generation of adenovirus
prolongs bFGF expression, it might be necessary to assess
the positive and negative influences of long-term delivery of
human gene-derived bFGF.
Finally, we must address some other issues that the
present study did not resolve. One is the influence of this ex
vivo therapy at later times. Our data were limited to 28 days
after cell administration. In our previous study6 gene-
transduced cells were eliminated by 14 days after cell injec-
tion, although there is the possibility that chronic side
effects, such as oncogenesis and worsening of diabetic
retinopathy, could develop after day 28. A more important
issue is how to apply this protocol to clinical testing. In this
ex vivo therapy there is a strict therapeutic range of cell
numbers for administration, and injection of excess gene-
transduced cells possibly induces critical worsening of tissue
ischemia. However, it might be difficult to predict the
therapeutic range in human beings from the present data,
because there is large species difference between human
beings and rabbits. Thus additional experiments with larger
animals, such as nonhuman primates, are needed to esti-
mate the therapeutic range in human beings.
In conclusion, this study demonstrated that 5  106
gene-transduced fibroblasts is an appropriate number to
administer through the internal iliac artery in a rabbit
model of hind limb ischemia to promote appropriate devel-
opment of collateral vessels and minimize side effects. In
addition, this ex vivo gene transfer could not be repeated.
Since the present ex vivo therapy has a variety of advanta-
geous properties, we believe that suitable administration
would induce effective and safe development of collateral
vessels in lesions in human beings.
We thank Dr Junji Kishimoto (Department of Clinical
Bioinfomatics, The University of Tokyo) and Dr Yasuo
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